IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer

被引:21
|
作者
Westeel, V.
Lebitasy, M. P.
Mercier, M.
Girard, P.
Barlesi, F.
Blanchon, F.
Tredaniel, J.
Bonnette, P.
Woronoff-Lemsi, M. C.
Breton, J. L.
Azarian, R.
Falcoz, P. E.
Friard, S.
Geriniere, L.
Laporte, S.
Lemarie, E.
Quoix, E.
Zalcman, G.
Guigay, J.
Morin, F.
Milleron, B.
Depierre, A.
机构
[1] Univ Franche Comte, CHU Besancon, Serv Pneumol, F-25030 Besancon, France
[2] IFCT, Paris, France
[3] Univ Franche Comte, Serv Biomath, F-25030 Besancon, France
[4] Ctr Mutualiste Montsouris, Paris, France
[5] APHM, Marseille, France
[6] APHP Hop St Louis, Paris, France
[7] Ctr Hosp Foch, Suresnes, France
[8] CH Versailles, Versailles, France
[9] Hop Foch, Suresnes, France
[10] Ctr Hosp Lyon Sud, HCL, F-69310 Pierre Benite, France
[11] CHU Tours, Tours, France
[12] CHU Strasbourg, F-67000 Strasbourg, France
[13] CHU Caen, F-14000 Caen, France
[14] Inst Gustave Roussy, Villejuif, France
[15] APHP Hop Tenon, Paris, France
关键词
lung cancer; post-operative follow-up; randomised trial; surgery; non-small cell lung cancer;
D O I
10.1016/S0761-8425(07)91135-3
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background The authorities advocate a minimalist attitude towards the follow-up of resected bronchial carcinoma (clinical examination and chest x-ray). A survey showed that 70% of French respiratory physicians have chosen to use the CT scanner and often endoscopy. The published data are equivocal and are often based on retrospective studies. Lung cancer is a good model for a study of post-operative surveillance. Recurrences often occur in easily observed areas, they may be detected while still asymptomatic and are sometimes potentially curable. Second primary tumours may develop at the same site. Methods The Intergroupe Francophone de Cancerologie Thoracique (IFCT) has initiated a trial comparing simple follow-up (clinical examination, chest x-ray) with a more intensive followup (CT scan, fibreoptic bronchoscopy). The surveillance will take place every 6 months for 2 years and then annually until 5 years. Expected results The main aim is to determine whether intensive follow-up improves patient survival. The opposite question is equally important. If an expensive and demanding follow-up does not affect the chances of cure these results will influence our practice.
引用
收藏
页码:645 / 652
页数:8
相关论文
共 50 条
  • [21] Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer
    Nakagawa, K.
    Tada, H.
    Akashi, A.
    Yasumitsu, T.
    Iuchi, K.
    Taki, T.
    Kodama, K.
    BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 817 - 821
  • [22] Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review
    Alam, Naveed
    Darling, Gail
    Evans, William K.
    Mackay, Jean A.
    Shepherd, Frances A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 58 (02) : 146 - 155
  • [23] DNA ploidy as a prognostic marker in completely resected non-small cell lung cancer
    Mugüerza, JM
    Asenjo, JAL
    Díez, M
    Gómez, A
    Torres, A
    Granell, J
    Noguerales, F
    Balibrea, JL
    BRITISH JOURNAL OF SURGERY, 1998, 85 : 99 - 99
  • [24] Results of Comparing Seven Lymph Node Staging Systems in Completely Resected Non-small Cell Lung Cancer Patients
    Cai, J. -S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S229 - S230
  • [25] A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)
    Westeel, Virginie
    Quoix, Elisabeth
    Puyraveau, Marc
    Lavole, A.
    Braun, Denis
    Laporte, Silvy
    Bigay-Game, Laurence
    Pujol, Jean-Louis
    Ozenne, Gervais
    Riviere, Alain
    Douillard, Jean-Yves
    Lebeau, Bernard
    Debieuvre, Didier
    Poudenx, Michel
    David, Philippe
    Molinier, Olivier
    Zalcman, Gerard
    Lemarie, Etienne
    Morin, Franck
    Depierre, Alain
    Milleron, Bernard
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (12) : 2654 - 2664
  • [26] Precision follow-up for resected non-small-cell lung cancer: is it ready for prime time?
    Mercier, Olaf
    Barlesi, Fabrice
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2021, 60 (05) : 1232 - 1233
  • [27] Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer
    Sun, Jong-Mu
    Noh, Jae Myung
    Oh, Dongryul
    Kim, Hong Kwan
    Lee, Se-Hoon
    Choi, Yong Soo
    Pyo, Hongryull
    Ahn, Jin Seok
    Jung, Sin-Ho
    Ahn, Yong Chan
    Kim, Jhingook
    Ahn, Myung-Ju
    Zo, Jae Ill
    Shim, Young Mog
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : 1806 - 1813
  • [28] Randomized phase ii trial comparing chemoradiotherapy with chemotherapy for completely resected unsuspected N2-positive non-small cell lung cancer
    Sun, J-M.
    Ahn, M-J.
    Ahn, J. S.
    Kim, H. K.
    Ahn, Y. C.
    Zo, J. I.
    Shim, Y. M.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-A Trial
    Spira, A. I.
    Ardizzoni, A.
    Barlesi, F.
    Cho, B. C.
    De Marchi, P.
    Goto, Y.
    Kowalski, D.
    Lu, S.
    Paz-Ares, L.
    Spigel, D. R.
    Thomas, M.
    Leung, M.
    Baum, J.
    Zhou, W.
    Portella, S.
    Yang, J. Chih-Hsin
    Garon, E. B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S25 - S25
  • [30] Canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer: CANOPY-A trial.
    Spira, Alexander
    Ardizzoni, Andrea
    Barlesi, Fabrice
    Cho, Byoung Chul
    De Marchi, Pedro
    Goto, Yasushi
    Kowalski, Dariusz
    Lu, Shun
    Paz-Ares, Luis
    Spigel, David R.
    Thomas, Michael
    Turri, Sabine
    Rodrik-Outmezguine, Vanessa
    Zhou, Wen
    Kreisl, Terri
    Yang, James Chih-Hsin
    Garon, Edward B.
    CANCER RESEARCH, 2021, 81 (13)